A randomized trial of Mycobacterium w in severe sepsis
Authors:
- 1 February 2015
- journal article
- research article
- Published by Elsevier in Journal of Critical Care
- Vol. 30 (1) , 85-89
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Deciphering the Sepsis RiddleCritical Care Medicine, 2013
- Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe SepsisJAMA, 2013
- Decreased T-Cell Repertoire Diversity in SepsisCritical Care Medicine, 2013
- Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomesExpert Review of Anti-infective Therapy, 2012
- Drotrecogin Alfa (Activated) in Adults with Septic ShockNew England Journal of Medicine, 2012
- Immunosuppression in Patients Who Die of Sepsis and Multiple Organ FailureJAMA, 2011
- TLR signalingCell Death & Differentiation, 2006
- Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels*Critical Care Medicine, 2004
- Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling PathwayScience, 2003
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001